MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology

MAPT R406W increases tau T217 phosphorylation in absence of amyloid pathology

Abstract Objective Tau hyperphosphorylation at threonine 217 (pT217) in cerebrospinal fluid (CSF) has recently been linked to early amyloidosis and could serve as a highly sensitive biomarker for Alzheimer’s disease (AD). However, it remains unclear whether other tauopathies induce pT217 modificatio...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Chihiro Sato, Nipun Mallipeddi, Nupur Ghoshal, Brenton A. Wright, Gregory S. Day, Albert A. Davis, Albert H. Kim, Gregory J. Zipfel, Randall J. Bateman, Audrey Gabelle, Nicolas R. Barthélemy
Formato: article
Lenguaje:EN
Publicado: Wiley 2021
Materias:
Alzheimer's Disease
Tauopathies
tau phosphorylation
mass spectrometry
cerebrospinal fluid
biomarker
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Acceso en línea:https://doaj.org/article/11eeb562e9e94caa965224e960d99793
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/11eeb562e9e94caa965224e960d99793

Ejemplares similares